Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TXN | P10599 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10575979 | 0.84 | PDE10A (0.36) | SMN1; SMN2ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL10375560 | 0.79 | WDR5 (0.33) | KMT2AARNPC1RAB9AWDR5 | |
| SCHEMBL3377071 | 0.71 | DDB1 (0.45) | DDB1CRBNSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL10671585 | 0.71 | KMT2A (0.34) | SMN1; SMN2KMT2AMEN1ARNPC1 | |
| SCHEMBL10286385 | 0.70 | UGT2B17 (0.33) | — | |
| SCHEMBL10377631 | 0.70 | — | — | |
| SCHEMBL10376876 | 0.69 | — | — | |
| SCHEMBL10677922 | 0.69 | DDB1 (0.51) | DDB1CRBNALDH1A1 | |
| SCHEMBL7936342 | 0.69 | POLB (0.35) | SMN1; SMN2KMT2AMEN1ARNPC1 | |
| SCHEMBL10377532 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | claimed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | claimed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | claimed |
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| EP-0187977-B1 | TETRAHYDROQUINOLINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND ANTI-PEPTIC ULCER COMPOSITIONS CONTAING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-29 | — | — | EP | disclosed |
| US-4880815-A | GASTRIC JUICE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| US-4738970-A | Benzimidazolyl-thio-tetrahydroquinolines and anti-peptic ulcer compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-04-19 | — | — | US | disclosed |
| EP-0187977-A1 | Tetrahydroquinoline derivatives, process for preparing the same and anti-peptic ulcer compositions containg the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | DDB1 881/4885CRBN 3680/4885SMN1; SMN2 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.